Señales en vivo de APM.PA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (11 may 2023 @ 03:54):

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer...

Stats
Volumen de hoy	3.00
Volumen promedio	0.00
Capitalización de mercado	8.82M
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.706
ATR14	€0.00100 (0.00%)

Volumen Correlación

Largo: 0.00 (neutral)

Corto: 0.00 (neutral)

Signal:(100) Neutral

Aptorum Group Limited Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aptorum Group Limited Correlación - Moneda/Commodity

0.00
( neutral )

Aptorum Group Limited Finanzas

Annual	2022
Ingresos:	€1.30M
Beneficio Bruto:	€80 065.00 (6.18 %)
EPS:	€4.59

FY	2022
Ingresos:	€1.30M
Beneficio Bruto:	€80 065.00 (6.18 %)
EPS:	€4.59

FY	2021
Ingresos:	€1.54M
Beneficio Bruto:	€81 854.00 (5.31 %)
EPS:	€-0.0715

FY	2020
Ingresos:	€911 509
Beneficio Bruto:	€-103 514 (-11.36 %)
EPS:	€0.0224

Financial Reports:

No articles found.

Aptorum Group Limited

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.